Francisco Rita, Pascoal Carlota, Marques-da-Silva Dorinda, Brasil Sandra, Pimentel-Santos Fernando M, Altassan Ruqaiah, Jaeken Jaak, Grosso Ana Rita, Dos Reis Ferreira Vanessa, Videira Paula A
CDG & Allies-Professionals and Patient Associations International Network (CDG & Allies-PPAIN), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, 2825-149 Lisbon, Portugal.
UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa Caparica, Caparica, 2825-149 Lisbon, Portugal.
J Clin Med. 2020 Jul 3;9(7):2092. doi: 10.3390/jcm9072092.
Congenital disorders of glycosylation (CDG) are rare diseases with variable phenotypes and severity. Immunological involvement remains a largely uncharted topic in CDG, mainly due to lack of robust data. To better characterize immune-related manifestations' prevalence, relevance, and quality-of-life (QoL) impact, we developed electronic questionnaires targeting (1) CDG patients and (2) the general "healthy" population. Two-hundred and nine CDG patients/caregivers and 349 healthy participants were included in this study. PMM2-CDG was the most represented CDG ( = 122/209). About half of these participants ( = 65/122) described relevant infections with a noteworthy prevalence of those affecting the gastrointestinal tract (GI) (63.1%, = 41/65). Infection burden and QoL impact were shown as infections correlated with more severe clinical phenotypes and with a set of relevant non-immune PMM2-CDG signs. Autoimmune diseases had only a marginal presence in PMM2-CDG (2.5%, = 3/122), all being GI-related. Allergy prevalence was also low in PMM2-CDG (33%, = 41/122) except for food allergies (26.8%, = 11/41, of PMM2-CDG and 10.8%, = 17/158, of controls). High vaccination compliance with greater perceived ineffectiveness (28.3%, = 17/60) and more severe adverse reactions were described in PMM2-CDG. This people-centric approach not only confirmed literature findings, but created new insights into immunological involvement in CDG, namely by highlighting the possible link between the immune and GI systems in PMM2-CDG. Finally, our results emphasized the importance of patient/caregiver knowledge and raised several red flags about immunological management.
先天性糖基化障碍(CDG)是一类罕见疾病,其表型和严重程度各异。免疫相关问题在CDG中仍是一个很大程度上未被探索的领域,主要原因是缺乏有力的数据。为了更好地描述免疫相关表现的患病率、相关性及其对生活质量(QoL)的影响,我们针对(1)CDG患者和(2)一般“健康”人群设计了电子问卷。本研究纳入了209名CDG患者/照料者和349名健康参与者。PMM2-CDG是最常见的CDG类型(=122/209)。这些参与者中约一半(=65/122)描述了有相关感染,其中影响胃肠道(GI)的感染患病率值得关注(63.1%,=41/65)。感染负担和对生活质量的影响表现为感染与更严重的临床表型以及一组相关的非免疫性PMM2-CDG体征相关。自身免疫性疾病在PMM2-CDG中仅占少数(2.5%,=3/122),且均与胃肠道相关。PMM2-CDG中的过敏患病率也较低(33%,=41/122)。食物过敏除外(PMM2-CDG为26.8%,=11/41,对照组为10.8%,=17/158)。PMM2-CDG患者的疫苗接种依从性较高,但感觉疫苗效果较差(28.3%,=17/60),且不良反应更严重。这种以患者为中心的方法不仅证实了文献中的发现,还为CDG中的免疫相关问题带来了新的见解,即突出了PMM2-CDG中免疫和胃肠道系统之间可能的联系。最后,我们的结果强调了患者/照料者知识的重要性,并对免疫管理提出了几个警示信号。